

Special Issue

Periprosthetic Joint Infections: Antimicrobial Biomaterials and Antibiotic Treatment

Message from the Guest Editor

Dear Colleagues, The last International Consensus Meeting in Istanbul taught us something key: there is major global interest in prevention, diagnosis, antibiotic therapy, and surgical treatment in periprosthetic joint infections (PJIs). Advances, innovations, and new techniques have enhanced the management of PJIs over the last two decades, but there is still a long way to go. I am excited to be collaborating with *Antibiotics* to bring you this Special Issue on PJIs. Articles related to antimicrobial biomaterials, associated in vitro and clinical studies, surgical techniques, local and systemic antibiotic therapy, and more will be considered for publication. Original research articles are welcome, as well as review articles. I am looking forward to working with you.

Guest Editor

Prof. Dr. Konstantinos Anagnostakos

Abteilung für Gelenkchirurgie und Sporttraumatologie, Nardini Klinikum
St. Elisabeth, Zweibrücken, Germany

Deadline for manuscript submissions

30 September 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/265939

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)